Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Danielle Elbert

Physician Assistant Evans, GA Physician Assistant

NPI 1336768357 CMS profile 11310038

902 Ponder Place Ct, Evans, GA 30809

Open in the dashboard

General payments

$7,996

327 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Elbert of Evans, GA is reported in the CMS Open Payments database as having received $7,996 across 327 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,493 95
2024 General $2,501 109
2023 General $1,936 76
2022 General $1,066 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Elbert
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Danielle Elbert were reported at $2,493. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Danielle Elbert Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,066 $155 $48–$522 $149
2023 $1,936 $167 $52–$557 $160
2024 $2,501 $178 $55–$600 $164
2025 $2,493 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Regeneron Healthcare Solutions, Inc. $1,656 51 payments
  2. Genzyme Corporation $719 33 payments
  3. Janssen Biotech, Inc. $706 34 payments
  4. UCB, Inc. $649 24 payments
  5. Sun Pharmaceutical Industries Inc. $642 17 payments
  6. LEO Pharma Inc. $604 30 payments
  7. Amgen Inc. $595 22 payments
  8. AbbVie, Inc. $484 26 payments
  9. Novartis Pharmaceuticals Corporation $355 15 payments
  10. Lilly USA, LLC $323 14 payments
  11. Other $1,263 61 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,221 316 payments
  2. Education $775 11 payments
Products named General payments · program years 2022–2025
  1. DUPIXENT Inflammation And Immunology $1,254 41 payments
  2. DUPIXENT Immunology $1,070 50 payments
  3. TREMFYA $719 35 payments
  4. Otezla $595 22 payments
  5. Bimzelx $559 21 payments
  6. ADBRY $525 27 payments
  7. ILUMYA $457 15 payments
  8. CIBINQO $291 17 payments
  9. OPZELURA $272 12 payments
  10. SKYRIZI $266 15 payments
  11. Other $2,454 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,750

Median for Physician Assistant: 241

Drug cost

$998,272

Median for Physician Assistant: $4,110

Branded share of claims

16.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 115 $523,824
Humira(Cf) Pen Adalimumab Brand 14 $190,730
Otezla Apremilast Brand 28 $162,884
Taltz Autoinjector Ixekizumab Brand 12 $83,084
Tacrolimus Generic 102 $9,794
Ketoconazole Generic 573 $7,141
Clobetasol Propionate Generic 176 $5,309
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 42 $2,436
Triamcinolone Acetonide Generic 189 $1,873
Fluorouracil Generic 28 $1,726

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$122,116

Medicare's payments for the services billed

Medicare patients

715

Average age 75

Services billed

3,988

383 women, 332 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 30%
Ischemic heart disease 25%
Chronic kidney disease 25%
Depression 21%
Atrial fibrillation 18%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $511
  • GENZYME CORPORATION $232
$743 115 —
Bimzelx
  • UCB, Inc. $230
$230 — —
TREMFYA
  • Janssen Biotech, Inc. $222
$222 — —
ADBRY
  • LEO Pharma Inc. $192
$192 — —
SKYRIZI
  • AbbVie, Inc. $166
$166 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

327 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record